For our 70th episode, we review a paper in the Journal of the Endocrine Society that tries to improve our understanding of remission in Graves' disease. Long-term thionamide treatment has long been the preferred approach internationally in Graves' disease, and only more recently here in the U.S. So, the more we know about dosing and how that might encourage or predict remission, the better. This report is an observational study, as is often the case with the papers we look at, so we will discuss how these authors approach this question and share our thoughts along the way. Host Chase Hendrickson, MD, MPH, MHCC, from Vanderbilt University, talks with regular contributor Andy Crawford, MD, from Dartmouth-Hitchcock Medical Center, and guest expert Giuseppe Barbesino, MD, from Harvard Medical School in Boston. They discussby Miyamura et al., published in the August 2025 issue of JCEM. Show notes can be found at— podcast home page:.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related